Spain’s Revalmed-SNS Network to Include Economic Evaluations in Therapeutic Positioning Reports

Country: SPAIN | Region: EUROPE | Type: HTA | Keywords: #aemps #costeffectivenessthresholds #economicmodeling #innovation #oncology #pricingandreimbursement
#revalmed #sns #therapeuticpositioningreports


PRICENTRIC BRIEF:
  • Patricia Lacruz, Director-General of Basic Portfolio of Services of Spain’s National Health System (SNS) and Pharmacy announced that Spain will be following a new economic model for evaluating innovative medicines
  • The initiative, Revalmed-SNS, will include economic evaluations in Spain’s Therapeutic Positioning Reports (TPRs), which will be fundamental for pricing and reimbursement negotiations going forward
  • It will take no more than 90 days to publish a TPR, which will include a new drug’s therapeutic position, clinical benefit, safety, and therapeutic alternatives, all in comparison to already-reimbursed medicines, and the drug under assessment will be given a score and ultimately a recommendation or rejection from the Revalmed-SNS committee

THE DETAILS

MADRID, Spain – Patricia Lacruz, Director-General of Basic Portfolio of Services of Spain’s National Health System (SNS) and Pharmacy announced that Spain will be following a new economic model for evaluating innovative medicines.

The initiative, Revalmed-SNS, will include economic evaluations in Spain’s Therapeutic Positioning Reports (TPRs), which will be fundamental for pricing and reimbursement negotiations going forward.

Spanish industry experts recently suggested that TPRs could potentially help streamline local drug evaluation, following a qualitative study that leaned in favor of the notion. The experts explained that hospital reports and similar documents at the regional level could be completed in a more agile way if TPRs were used as a reference, and so reasoned that they could be used as a tool to facilitate access to new drugs by accelerating the evaluated process.

Revalmed-SNS will be comprised of a therapeutic evaluation group, an economic evaluation group, and therapeutic area specialists. In addition, as Lacruz previously mentioned, the Basic Portfolio of SNS and Hospital Services, the Spanish Medicines Agency (AEMPS), and Spain’s autonomous communities themselves will be involved.

It will take no more than 90 days to publish a TPR. The TPRs will include a new drug’s therapeutic position, clinical benefit, safety, and therapeutic alternatives, all in comparison to already-reimbursed medicines. Each drug will then be given a score.

Through TPRs, Spain seeks to establish a cost-effectiveness threshold. The Spanish Society of Hospital Pharmacy (SEFH) will contribute to this methodology by reviewing published evaluations, and Spain will consider budgetary impact and target populations.

The 90-day process will be completed in three phases. First, stakeholders, including scientific societies, patient groups, and companies, will offer their expert opinion. Then, Revalmed-SNS’ therapeutic and economic evaluation groups will review the TRP.

Learn more about Pricentric ONE and our Global Pricing Solutions!

Contact us with your questions and global pricing needs, and an expert will follow up shortly.